DavidALiebnerMD

Oncology • Columbus, OH

Assistant Professor, Internal Medicine, Ohio State University College of Medicine

Join to view full profile

Dr. Liebner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Liebner's full profile

Already have an account?

Office
460 W 10th Ave
Columbus, OH 43210
Phone+1 614-293-6529

Fax+1 614-293-9469

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2010 - 2013
University at BuffaloResidency, Internal Medicine, 2007 - 2010
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 2007

Certifications & Licensure

OH State Medical License 2010 - 2026
American Board of Internal Medicine Medical Oncology

Clinical Trials

Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Start of enrollment: 2012 Nov 09
Completed
Phase 1
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes Start of enrollment: 2014 Jul 01
Completed
Phase 2
A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma Start of enrollment: 2016 Mar 01
Completed
Phase 1, Phase 2
An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry Start of enrollment: 2015 Jul 01
Recruiting
Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma Start of enrollment: 2016 Dec 06
Completed
Phase 2
MAGE-A4ᶜ¹º³²T for Multi-Tumor Start of enrollment: 2017 May 15
Active, not recruiting
Phase 1
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Start of enrollment: 2019 Aug 13
Recruiting
Phase 2
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) Start of enrollment: 2023 Nov 29
Recruiting
Phase 3
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and cor...
Nathan D Seligson, James L Chen, Austin C Goodrich, Brian A Van Tine, Jordan D Campbell
Journal for Immunotherapy of Cancer. 2024-09-28
Use of neoadjuvant paclitaxel in breast angiosarcoma-Impact on surgical resection and response rates.
Luke V Selby, Emma Clark, James L Chen, Gabriel Tinoco, Joal D Beane
Journal of Surgical Oncology. 2024-09-01
Clinical Characteristics, Patterns of Care, and Treatment Outcomes of Radiation-Associated Sarcomas.
Rohit Raj, Han Gil Kim, Menglin Xu, Tyler Roach, David Liebner
Cancers. 2024-05-18